Comorbidities in Patients with Spondyloarthritis

Rheumatic Disease Clinics of North America

Volumn 38, Issue 3, 2012, Pages 523-538

  van der Horst Bruinsma, Irene E ^a,b   Nurmohamed, Michael T ^a,b   Landewé, Robert B M ^c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Jan Van Breemen Research Institute   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Ankylosing spondylitis; Cardiovascular disease; Cardiovascular risk management; Inflammatory bowel disease; Myocardial infarction; Psoriasis; Spondyloarthritis; Uveitis

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; AZATHIOPRINE; CORTICOSTEROID; ETANERCEPT; GOLIMUMAB; HLA B27 ANTIGEN; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MYDRIATIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE; PSORALEN; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR INHIBITOR;

ANKYLOSING SPONDYLITIS; AORTA VALVE REGURGITATION; ARTERIAL WALL THICKENING; ARTERIAL WALL THICKNESS; ARTHRITIS; ATHEROSCLEROSIS; BONE DENSITY; CARDIOVASCULAR RISK; COHORT ANALYSIS; COMORBIDITY; CROHN DISEASE; DRUG ACTIVITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ENDOSCOPY; ENTERITIS; EYE PAIN; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; KINESIOTHERAPY; MEDICAL SPECIALIST; MONARTHRITIS; MORTALITY; OSTEOPOROSIS; PATIENT REFERRAL; PERIPHERAL ARTHRITIS; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; PSORIASIS; REVIEW; RISK ASSESSMENT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPONDYLARTHRITIS; SYMPTOMATOLOGY; ULCERATIVE COLITIS; ULTRAVIOLET A RADIATION; UVEITIS;

ACUTE DISEASE; ANTIBODIES, MONOCLONAL; ARTHRITIS; CARDIOVASCULAR DISEASES; COMORBIDITY; HUMANS; INFLAMMATORY BOWEL DISEASES; PSORIASIS; REFERRAL AND CONSULTATION; SACROILIAC JOINT; SPINE; SPONDYLARTHRITIS; SPONDYLITIS, ANKYLOSING; SYNOVITIS; UVEITIS, ANTERIOR;

EID: 84867818808     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2012.08.010     Document Type: Review

References (105)

1. Rudwaleit M., van der Heijde D., Landewé R., et al. The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009, 68:777-783.
2. Rudwaleit M., van der Heijde D., Landewé R., et al. The assessment of Spondyloarthritis International Society Classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2011, 70:25-31.
3. Van der Linden S., Valkenburg H.A., Cats A. Evaluation of the diagnostic criteria for ankylosing spondylitis; a proposal for the modification of the New York criteria. Arthritis Rheum 1984, 27:361-368.
4. Braun J., Bollow M., Remlinger G., et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998, 41:58-67.
5. McGonagle D., Khan M.A., Marzo-Ortega H., et al. Enthesitis in ankylosing spondylitis and related spondylarthropathies. Curr Opin Rheumatol 1999, 11:244-250.
6. Heuft-Dorenbosch L., Spoorenberg A., Tubergen A., et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003, 62:127-132.
7. Maksymowych W.P., Mallon C., Morrow S., et al. Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index. Ann Rheum Dis 2009, 68(6):948-953.
8. van der Weijden M.A., Claushuis T.A., Nazari T., et al. High prevalence of low bone mineral density in patients within 10 years of onset of ankylosing spondylitis: a systematic review. Clin Rheumatol 2012, [Epub ahead of print].
9. van der Weijden M.A., van der Horst-Bruinsma I.E., van Denderen J.C., et al. High frequency of vertebral fractures in early spondylarthropathies. Osteoporos Int 2012, 23(6):1683-1690.
10. El Maghraoui A. Extra-articular manifestations of ankylosing spondylitis: prevalence, characteristics and therapeutic implications. Eur J Intern Med 2011, 22(6):554-560.
11. Dougados M., Behier J.M., Jolchine I., et al. Efficacy of celecoxib, a cycloogynase-2-specific inhibitor, in the treatment of ankylosing spondylitis. Arthritis Rheum 2001, 44:180-185.
12. van der Heijde D., Baraf H.S., Ramos-Remus C., et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum 2005, 52:1205-1215.
13. Wanders A., Heijde D., Landewe R., et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005, 52:1756-1765.
14. Poddubnyy D., Rudwaleit M., Haibel H., et al. Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German spondyloarthritis inception cohort. Ann Rheum Dis 2012, [Epub ahead of print].
15. Zochling J., van der Heijde D., Dougados M., et al. Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis 2006, 65(4):423-432.
16. Braun J., van der Horst-Bruinsma I.E., Huang F., et al. Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Arthritis Rheum 2011, 63(6):1543-1551.
17. Song I.H., Hermann K., Haibel H., et al. Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. Ann Rheum Dis 2011, 70(4):590-596. [Erratum in Ann Rheum Dis 2011;70(7):1350].
18. van der Heijde D., Dijkmans B., Geusens P., et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005, 52:582-591. Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group.
19. van der Heijde D., Da Silva J.C., Dougados M., et al. Once-weekly 50-mg dosing of etanercept (Enbrel(R)) is as effective as 25-mg twice-weekly dosing in patients with ankylosing spondylitis. Ann Rheum Dis 2006, 65(12):1572-1577.
20. Van der Heijde D., Kivitz A., Schiff M.H., et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis. Results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006, 54:2136-2146.
21. Inman R.D., Davis J.C., Heijde D., et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008, 58:3402-3412.
22. Brandt J., Khariouzov A., Listing J., et al. Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept. J Rheumatol 2004, 31(3):531-538.
23. Baraliakos X., Listing J., Brandt J., et al. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 2005, 7(3):R439-R444. [Erratum in Arthritis Res Ther 2005;7(3):113].
24. Haibel H., Rudwaleit M., Listing J., et al. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis 2005, 64(2):296-298.
25. Tan A.L., Marzo-Ortega H., O'Connor P., et al. Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. Ann Rheum Dis 2004, 63(9):1041-1045.
26. Song I.H., Heldmann F., Rudwaleit M., et al. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum 2010, 62(5):1290-1297.
27. Lekpa F.K., Farrenq V., Canouï-Poitrine F., et al. Lack of efficacy of abatacept in axial spondylarthropathies refractory to tumor-necrosis-factor inhibition. Joint Bone Spine 2012, 79(1):47-50.
28. Song I.H., Heldmann F., Rudwaleit M., et al. Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Ann Rheum Dis 2011, 70(6):1108-1110.
29. Braun J., Landewé R., Hermann K.G., et al. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum 2006, 54(5):1646-1652.
30. Baraliakos X., Davis J., Tsuji W., et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept. Arthritis Rheum 2005, 52(4):1216-1223.
31. Lambert R.G., Salonen D., Rahman P., et al. Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter randomized, double-blind, placebo-controlled study. Arthritis Rheum 2007, 56(12):4005-4014.
32. Braun J., Baraliakos X., Hermann K.G., et al. Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo-controlled GO-RAISE study. Ann Rheum Dis 2012, 71(6):878-884.
33. Rudwaleit M., Claudepierre P., Wordsworth P., et al. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol 2009, 36(4):801-808.
34. Vastesaeger N., van der Heijde D., Inman R.D., et al. Predicting the outcome of ankylosing spondylitis therapy. Ann Rheum Dis 2011, 70(6):973-981.
35. Haibel H., Rudwaleit M., Listing J., et al. Efficacy of adalimumab in the treatment of axial spondyloarthritis without radiographically defined sacroiliitis. Arthritis Rheum 2008, 58:1981-1991.
36. Barkham N., Keen H.I., Coates L.C., et al. Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum 2009, 60(4):946-954. [Erratum in Arthritis Rheum 2010;62(10):3005].
37. Barnabe C., Hanley D.A. Effect of tumor necrosis factor alpha inhibition on bone density and turnover markers in patients with rheumatoid arthritis and spondyloarthropathy. Semin Arthritis Rheum 2009, 39(2):116-122.
38. Linder R., Hoffmann A., Brunner R. Prevalence of the spondyloarthritides in patients with uveitis. J Rheumatol 2004, 31(11):2226-2229.
39. Monnet D., Breban M., Hudry C., et al. Ophthalmic findings and frequency of extraocular manifestations in patients with HLA-B27 uveitis: a study of 175 cases. Ophthalmology 2004, 111(4):802-809.
40. Pato E., Banares A., Jover J.A., et al. Undiagnosed spondyloarthropathy in patients presenting with anterior uveitis. J Rheumatol 2000, 27(9):2198-2202.
41. Linssen A., Rothova A., Valkenburg H.A., et al. The lifetime cumulative incidence of acute anterior uveitis in a normal population and its relation to ankylosing spondylitis and histocompatibility antigen HLA-B27. Invest Ophthalmol Vis Sci 1991, 32(9):2568-2578.
42. Munoz-Fernandez S., Hidalgo V., Fernandez-Melon J., et al. Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period. J Rheumatol 2003, 30(6):1277-1279.
43. Wakefield D., Chang J.H., Amjadi S., et al. What is new HLA-B27 acute anterior uveitis?. Ocul Immunol Inflamm 2011, 19(2):139-144.
44. El-Shabrawi Y., Hermann J. Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis. Ophthalmology 2002, 109(12):2342-2346.
45. Braun J., Baraliakos X., Listing J., et al. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005, 52(8):2447-2451.
46. Foster C.S., Tufail F., Waheed N.K., et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol 2003, 121(4):437-440.
47. Rosenbaum J.T. Effect of etanercept on iritis in patients with ankylosing spondylitis. Arthritis Rheum 2004, 50(11):3736-3737.
48. Sieper J., Koenig A., Baumgartner S., et al. Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials. Ann Rheum Dis 2010, 69(1):226-229.
49. Rudwaleit M., Rødevand E., Holck P., et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis 2009, 68(5):696-701.
50. van der Horst-Bruinsma I.E., van Denderen J.C., Visman I., et al. Decreased recurrence rate of uveitis in ankylosing spondylitis treated with adalimumab-an interim analysis. Clin Exp Rheumatol 2010, 28:630.
51. Khan M.A. Clinical features of ankylosing spondylitis. Rheumatology 2003, vol. 2:1161-1181. Mosby, Edinburg (TX).
52. Gossec L., Smolen J.S., Gaujoux-Viala C., et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012, 71(1):4-12. European League Against Rheumatism.
53. Nash P., Thaçi D., Behrens F., et al. Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study. Dermatology 2006, 212(3):238-249.
54. Kary S., Worm M., Audring H., et al. New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists. Ann Rheum Dis 2006, 65(3):405-407.
55. Mielants H., Veys E.M., Cuvelier C., et al. Ileocolonoscopy and spondarthritis. Br J Rheumatol 1988, 27(2):163-164.
56. Mielants H., Veys E.M., Goemaere S., et al. Gut inflammation in the spondyloarthropathies: clinical, radiologic, biologic, and genetic features in relation to the type of histology. A prospective study. J Rheumatol 1991, 18(10):1542-1551.
57. de Vries M., van der Horst-Bruinsma I., van Hoogstraten I., et al. pANCA, ASCA, and OmpC antibodies in patients with ankylosing spondylitis without inflammatory bowel disease. J Rheumatol 2010, 37(11):2340-2344.
58. Sandborn W.J., Stenson W.F., Brynskov J., et al. Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. Clin Gastroenterol Hepatol 2006, 4(2):203-211.
59. van der Horst-Bruinsma I.E., Clegg D.O., Dijkmans B.A. Treatment of ankylosing spondylitis with disease modifying antirheumatic drugs. Clin Exp Rheumatol 2002, 20:S67-S70.
60. Braun J., Baraliakos X., Listing J., et al. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum 2007, 57(4):639-647.
61. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359(9317):1541-1549.
62. Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353(23):2462-2476. [Erratum in N Engl J Med 2006 18;354(20):2200].
63. Sandborn W.J., Rutgeerts P., Enns R., et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007, 146(12):829-838.
64. Sandborn W.J., Hanauer S.B., Rutgeerts P., et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007, 56(9):1232-1239.
65. Sandborn W.J., Hanauer S.B., Katz S., et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001, 121(5):1088-1094.
66. Song I.H., Appel H., Haibel H., et al. New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept. J Rheumatol 2008, 35(3):532-536. [Erratum in J Rheumatol 2008;35(4):729].
67. Hahn B.H., Grossman J., Chen W., et al. The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J Autoimmun 2007, 28:69-75.
68. Bakland G., Gran J.T., Nossent J.C. Increased mortality in ankylosing spondylitis is related to disease activity. Ann Rheum Dis 2011, 70:1921-1925.
69. Mok C.C., Kwok C.L., Ho L.Y., et al. Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong, China. Arthritis Rheum 2011, 63:1182-1189.
70. Peters M.J., van der Horst-Bruinsma I.E., Dijkmans B.A., et al. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 2004, 34:585-592.
71. Zochling J., Braun J. Mortality in rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 2009, 27(4 Suppl 55):S127-S130.
72. Symmons D.P., Goodson N.J., Cook M.N., et al. Men with ankylosing spondylitis have an increased risk of myocardial infarction. Arthritis Rheum 2004, 50(Suppl):S477.
73. Szabo S.M., Levy A.R., Rao S.R., et al. Increased risk of cardiovascular and cerebrovascular disease in individuals with ankylosing spondylitis: a population-based study. Arthritis Rheum 2011, 63:3294-3304.
74. Peters M.J., Visman I., Nielen M.M. Ankylosing spondylitis; a risk factor for myocardial infarction?. Ann Rheum Dis 2010, 69:579-581.
75. Bremander A., Petersson I.F., Bergman S., et al. Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis. Arthritis Care Res 2011, 63:550-556.
76. Zöller B., Li X., Sundquist J., et al. Risk of subsequent ischemic and hemorrhagic stroke in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from Sweden. BMC Neurol 2012, 12(1):41.
77. Gonzalez-Juanatey C., Vazquez-Rodriguez T.R., Miranda-Filloy J.A., et al. The high prevalence of subclinical atherosclerosis in patients with ankylosing spondylitis without clinically evident cardiovascular disease. Medicine (Baltimore) 2009, 88:358-365.
78. Hamdi W., Chelli Bouaziz M., Zouch I., et al. Assessment of preclinical atherosclerosis in patients with ankylosing spondylitis. J Rheumatol 2012, 9:322-326.
79. Palazzi C., Salvarani C., D'Angelo S., et al. Aortitis and periaortitis in ankylosing spondylitis. Joint Bone Spine 2011, 78:451-455.
80. Brunner F., Kunz A., Weber U., et al. Ankylosing spondylitis and heart abnormalities: do cardiac conduction disorders, valve regurgitation and diastolic dysfunction occur more often in male patients with diagnosed ankylosing spondylitis for over 15 years than in the normal population?. Clin Rheumatol 2006, 25:24-29.
81. Park S.H., Sohn I.S., Joe B.H., et al. Early cardiac valvular changes in ankylosing spondylitis: a transesophageal echocardiography study. J Cardiovasc Ultrasound 2012, 20(1):30-36.
82. Youssef W., Russell A.S. Cardiac, ocular, and renal manifestations of seronegative spondylarthropathies. Curr Opin Rheumatol 1990, 2:582-585.
83. Peeters A.J., ten Wolde S., Sedney M.I., et al. Heart conduction disturbance: an HLA-B27 associated disease. Ann Rheum Dis 1991, 50:348-350.
84. Yildirir A., Aksoyek S., Calguneri M., et al. Echocardiographic evidence of cardiac involvement in ankylosing spondylitis. Clin Rheumatol 2002, 21:129-134.
85. Dik V.K., Peters M.J., Dijkmans P.A., et al. The relationship between disease-related characteristics and conduction disturbances in ankylosing spondylitis. Scand J Rheumatol 2010, 39:38-41.
86. Caliskan M., Erdogan D., Gullu H., et al. Impaired coronary microvascular and left ventricular diastolic functions in patients with ankylosing spondylitis. Atherosclerosis 2008, 196:306-312.
87. Yalcin H., Guler H., Gunay E., et al. Left ventricular wall function abnormalities in patients with ankylosing spondylitis evaluated by gated myocardial perfusion scintigraphy. Rev Esp Med Nucl 2011, 30:292-296.
88. Han C., Robinson D.W., Hackett M.V., et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006, 33:2167-2172.
89. Kang J.H., Chen Y.H., Lin H.C. Comorbidity profiles among patients with ankylosing spondylitis: a nationwide population-based study. Ann Rheum Dis 2010, 69:1165-1168.
90. Mathieu S., Gossec L., Dougados M., et al. Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Care Res 2011, 63:557-563.
91. Divecha H., Sattar N., Rumley A., et al. Cardiovascular risk parameters in men with ankylosing spondylitis in comparison with non-inflammatory control subjects: relevance of systemic inflammation. Clin Sci 2005, 109:171-176.
92. Papadakis J.A., Sidiropoulos P.I., Karvounaris S.A., et al. High prevalence of metabolic syndrome and cardiovascular risk factors in men with ankylosing spondylitis on anti-TNF alpha treatment: correlation with disease activity. Clin Exp Rheumatol 2009, 27:292-298.
93. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005, 352:1685-1695.
94. Angel K., Provan S.A., Gulseth H.L., et al. Tumor necrosis factor-alpha antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study. Hypertension 2010, 55:333-338.
95. Angel K., Provan S.A., Fagerhol M.K., et al. Effect of 1-Year anti-TNF-α therapy on aortic stiffness, carotid atherosclerosis, and calprotectin in inflammatory arthropathies: a controlled study. Am J Hypertens 2012, 25(6):644-650.
96. van Eijk I.C., Peters M.J., Serné E.H., et al. Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor alpha blockade. Ann Rheum Dis 2009, 68:362-366.
97. Syngle A., Vohra K., Sharma A., et al. Endothelial dysfunction in ankylosing spondylitis improves after tumor necrosis factor-alpha blockade. Clin Rheumatol 2010, 29:763-770.
98. Senel S., Cobankara V., Taskoylu O., et al. Effect of infliximab treatment on QT intervals in patients with ankylosing spondylitis. J Investig Med 2011, 59:1273-1275.
99. Spanakis E., Sidiropoulos P., Papadakis J., et al. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J Rheumatol 2006, 33:2440-2446.
100. Kiortsis D.N., Mavridis A.K., Filippatos T.D., et al. Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 2006, 33:921-923.
101. Mathieu S., Dubost J.J., Tournadre A., et al. Effects of 14 weeks of TNF alpha blockade treatment on lipid profile in ankylosing spondylitis. Joint Bone Spine 2010, 77:50-52.
102. van Eijk I., de Vries M.K., Levels J.H., et al. Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis. Arthritis Rheum 2009, 60:1324-1330.
103. Redelmeier D.A., Tan S.H., Booth G.L. The treatment of unrelated disorders in patients with chronic medical diseases. N Engl J Med 1998, 338:1516-1520.
104. Peters M.J., Symmons D.P., McCarey D., et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010, 69:325-331.
105. Braun J., vd Berg R., Baraliakos X., et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011, 70:896-904.